R&D Costs, Reimbursement Challenges in War Against Bugs
By Mari Serebrov
Thursday, January 31, 2013
Hoping to gain some ground in an all-out war against superbugs, the FDA is taking the first steps toward creating an approval shortcut for new antimicrobials with a public hearing Feb. 4.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.